Kingsview Wealth Management’s Ginkgo Bioworks DNA Stock Holding History
Bought
Maintained
Sold
Other funds holding DNA
AIM
ACG
NAMA
Kingsview Wealth Management's DNA Position: Q4 2023 in Review
Kingsview Wealth Management sold out of Ginkgo Bioworks (DNA) in Q4 2023, closing a stake of 1,304 shares — an estimated $94.4K sold.
Kingsview Wealth Management first reported a position in DNA in Q3 2023 and held it in 1 quarter. The position peaked at $94.4K in Q3 2023. 342 funds tracked by Wall St. Rank hold DNA as of Q4 2023.
- Kingsview Wealth Management reported no remaining Ginkgo Bioworks position as of Q4 2023 after selling out during the quarter.
- Kingsview Wealth Management sold 1,304 Ginkgo Bioworks shares in Q4 2023, an estimated $94.4K.
- Kingsview Wealth Management first reported a position in Ginkgo Bioworks in Q3 2023 and held it in 1 quarter.
- Kingsview Wealth Management's Ginkgo Bioworks position peaked at $94.4K in Q3 2023.
- 342 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q4 2023.
Based on Kingsview Wealth Management's 13F filing for Q4 2023, filed 8 Feb 2024.